Article ; Online: Flu-like syndrome due to interferon-beta injections does not increase anxiety, depression, and lost working days in multiple sclerosis patients during the Sars-CoV-2 pandemic.
Clinical neurology and neurosurgery
2023 Volume 232, Page(s) 107892
Abstract: Background and purpose: Aim of this study was to evaluated anxiety, depression, and possible negative implications on work activities during the Sars-CoV-2 pandemic, in a group of Multiple Sclerosis (MS) patients at risk of flu-like syndrome (FLS) ... ...
| Abstract | Background and purpose: Aim of this study was to evaluated anxiety, depression, and possible negative implications on work activities during the Sars-CoV-2 pandemic, in a group of Multiple Sclerosis (MS) patients at risk of flu-like syndrome (FLS) compared with FLS- free treatments. Methods: The present study included patients treated with interferon-ß (IFNß), glatiramer, and natalizumab for at least one year. Collected data included the diagnosis of COVID-19 infection, Beck Depression Inventory-II (BDI-II), Beck Anxiety Inventory (BAI), together with questions about FLS, change in work habits, use of antipyretics, anxiety, and depression. Results: 100 patients were included in the study. Six patients in IFNß and 5 in the natalizumab group had a confirmed COVID-19 infection. 68% in the IFNß patients reported FLS and only one reported an increase in flu-like frequency during the pandemic; 14% reported lower compliance with treatment, and 40% reported uptake of antipyretics several times. Only one IFNß patient reported having lost more working days than the previous year. The average BAI (p = 0.039) was higher in natalizumab group. Correcting these data by age, sex and EDSS to a multivariate analysis we did not find any statistically significant difference in terms of BAI and BDI-II between the three treatment groups. Conclusions: FLS were not perceived as COVID19-like symptoms but as expected by traditional pharmacological treatments indeed. These data suggest that IFNß can be used safely. |
|---|---|
| MeSH term(s) | Humans ; Multiple Sclerosis/drug therapy ; Interferon-beta/adverse effects ; SARS-CoV-2 ; Natalizumab/therapeutic use ; Depression/epidemiology ; Depression/diagnosis ; Pandemics ; Antipyretics/therapeutic use ; COVID-19/epidemiology ; Anxiety/chemically induced ; Anxiety/epidemiology ; Anxiety/diagnosis |
| Chemical Substances | Interferon-beta (77238-31-4) ; Natalizumab ; Antipyretics |
| Language | English |
| Publishing date | 2023-07-13 |
| Publishing country | Netherlands |
| Document type | Journal Article |
| ZDB-ID | 193107-6 |
| ISSN | 1872-6968 ; 0303-8467 |
| ISSN (online) | 1872-6968 |
| ISSN | 0303-8467 |
| DOI | 10.1016/j.clineuro.2023.107892 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Ui I Zs.53: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.